Inhibition of the IGF-IR/InsR signaling pathway enhanced the action of AZD5363 against estrogen-deprived breast cancers, suggesting that combined treatment with an AKT inhibitor and a dual IGF-IR/InsR TKI merits evaluation as a potential treatment for endocrine-resistant breast cancer. This evidence concerns the gene INSR and breast cancer.